Welcome to our dedicated page for INNOVATIVE EYEWEAR SEC filings (Ticker: LUCYW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innovative Eyewear, Inc. filings document the public-company record for the smart eyewear issuer and its Nasdaq-listed common stock and warrants, including LUCYW warrants to purchase common stock. Material-event reports cover equity offering activity, legal opinions related to share issuance, warrant inducement agreements, resale registration references, and shareholder director-nomination procedures.
Proxy materials describe annual meeting governance matters, board elections, auditor ratification, control-share voting-rights items, charter amendments, and rights-plan matters. The filings also identify capital-structure subjects such as common stock par value, registered warrants, warrant terms, and securities listed on The Nasdaq Stock Market.
The company is updating its at-the-market common stock offering to allow sales of up to $2,679,217 of common stock through H.C. Wainwright & Co. under an existing sales agreement and shelf registration. This amount excludes approximately $1,202,269 of common stock already sold under earlier related prospectus supplements. The filing notes a public float of about $11,644,460, based on 3,298,714 shares held by non-affiliates at $3.53 per share as of June 20, 2025. The common stock trades on the Nasdaq Capital Market under the symbol LUCY, with a last reported price of $2.20 per share on August 14, 2025. Investors are directed to detailed risk factor discussions before purchasing shares.
Innovative Eyewear's Schedule 13G/A reports that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively beneficially own 475,728 shares of common stock, representing approximately 9.99% of the outstanding shares as of June 30, 2025. That total consists of 288,282 shares held by Intracoastal and 187,446 shares issuable upon exercise of Intracoastal Warrant 1. The filing discloses multiple additional warrant tranches excluded from the reported percentage because of blocker provisions, and states that without those blockers the group could be deemed to beneficially own 2,616,499 shares. The reporting persons indicate 0 sole voting power and shared voting and dispositive power over the reported 475,728 shares and certify the holdings were not acquired to change or influence control.
Innovative Eyewear, Inc. (Nasdaq: LUCY / LUCYW) filed an 8-K disclosing a cash-for-warrant inducement completed on 20 June 2025. The company persuaded holders of 746,782 existing warrants (originally issued 14 Apr 2025, strike $2.60) to exercise in full. In exchange, the holders purchased—at $0.125 per warrant—2,240,346 new Series I warrants ("New Warrants") that carry the same $2.60 exercise price, are immediately exercisable and expire 18 months after the related resale registration statement becomes effective.
Gross proceeds total approximately $2.2 million (≈ $1.94 million from warrant exercise plus ≈ $0.28 million from New Warrant purchase). Net proceeds will be lower after:
- Placement agent cash fee: 7.5 % of gross
- Management fee: 1.0 % of gross
- Expenses: $90,950 (accountable, non-accountable and clearing)
Placement agent H.C. Wainwright & Co. also received:
- 56,009 PA Warrants (strike $3.25, 18-month term)
- 73,990 Ordinary-Course PA Warrants (strike $3.25, expire 20 Jun 2030)
The company must file a resale registration statement for the New Warrant shares within 30 days and seek SEC effectiveness within 60 days (90 days if fully reviewed). It agreed to:
- Refrain from issuing or registering additional equity for 30 days
- Avoid variable-rate transactions for one year (limited exception)
Use of proceeds: working capital and general corporate purposes.
Capital structure impact: Immediately adds 746,782 common shares; a further 2,240,346 shares (plus 130,000+ PA-related shares) could enter the float if all new warrants are exercised, creating a sizeable potential dilution relative to the modest cash infusion.